Press Release

BALTIMORE, February 2 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed apatent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd.,and Sekisui Medical Co. Ltd. in the United States District Court for theNorthern District of Illinois in Chicago. XenoTech and Sekisui Medical arewholly-owned subsidiaries of Sekisui Chemical. The complaint alleges thatcertain processes and methods performed by XenoTech associated with its invitro drug testing services and its pooled cryopreserved hepatocyte products,including CryoXTreme(TM), infringes one or more claims of U.S. Patent No.7,604,929 (the '929 patent). The complaint also alleges that Sekisui Chemicaland Sekisui Medical are inducing infringement of the '929 patent and seeksmonetary damages and injunctive relief. Celsis IVT is represented by JordanSigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producingcryopreserved hepatocytes. In general, this technology combines hepatocytesfrom multiple donors to create large lots with targeted activity levels, theresult of which is a product that speeds up decision making and reduces thetime and cost of drug research. Since 2005, Celsis IVT has used this noveltechnology to create its unique LiverPool(TM) products for drug discoveryresearch. Major pharmaceutical companies around the world have incorporatedthese LiverPool products into their standard research protocols. Researchconducted with LiverPool has confirmed its outstanding efficacy as a researchtool in numerous ADME-Tox assays, including metabolic stability and clearancestudies. Additional LiverPool product information is available online atwww.celsis.com/liverpool.

"Innovation is the lifeblood of Celsis and the entire life sciencesindustry. It must be protected if we are to advance the cause ofcost-effective drug discovery," said Jay LeCoque, CEO of Celsis. "We aredisappointed that we are forced to take a litigation path after anunsuccessful attempt to meaningfully discuss our proprietary rights withXenoTech," he added, "Yet, we remain hopeful that the Defendants willcooperate with us to reach a successful resolution."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis International Ltd., is the premierworld provider of specialized in vitro products for the study of metabolism,drug-drug interactions and toxicity in drug discovery and development. Since1990, pharmaceutical and biotechnology companies have relied onBaltimore-based Celsis IVT for quality in vitro products for leadoptimization. Celsis IVT products deliver faster time to results, enablingmore productive and cost-effective research. Celsis IVT's patented LiverPoolproducts, cryo-plateable hepatocytes (the world's largest inventory) andother ADMET research tools are available worldwide. Visit www.celsis.com/ivtfor more information.

About Celsis International Ltd.

Chicago-based Celsis International Ltd. is a leading global provider ofinnovative life science products and laboratory services to thepharmaceutical and consumer products industries. Each Celsis divisiondelivers substantial time and cost savings to its customers while ensuringproduct quality and safety for consumers. Celsis' extensive client baseincludes leading pharmaceutical and consumer products companies, includingall 25 of the top 25 pharmaceutical companies worldwide. Visitwww.celsis.com.